Anti-inflammatory properties of antipsychotics via microglia modulations: Are antipsychotics a 'fire extinguisher' in the brain of schizophrenia?

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 7, 2011, Pages 565-574

  Kato, T A ^a,b   Monji, A ^a   Mizoguchi, Y ^a,c   Hashioka, S ^a,d   Horikawa, H ^a   Seki, Y ^a   Kasai, M ^a   Kasai, H ^a   Utsumi, H ^b   Kanba, S ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c SAGA UNIVERSITY   (Japan)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antipsychotics; Cytokines; Dopamine d2 receptors; Free radicals; Inflammation; Microglia; Oxidative stress; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUPENTIXOL; HALOPERIDOL; LOXAPINE; OLANZAPINE; PEROSPIRONE; QUETIAPINE; RISPERIDONE; SPIPERONE; TRIFLUPERIDOL; ZIPRASIDONE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASTROCYTE; CELL ACTIVATION; GLIOSIS; HUMAN; MICROGLIA; NEUROPROTECTION; NONHUMAN; SCHIZOPHRENIA;

ANTI-INFLAMMATORY AGENTS; ANTIPSYCHOTIC AGENTS; BRAIN; CYTOKINES; HUMANS; MICROGLIA; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 79959980999     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955711795906941     Document Type: Article

References (102)

1. Freedman, R. Schizophrenia. N. Engl. J. Med., 2003, 349(18), 1738-1749.
2. Graeber, M. B.; Streit, W. J. Microglia: biology and pathology. Acta Neuropathol., 2010, 119(1), 89-105.
3. Block, M. L.; Hong, J. S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol., 2005, 76(2), 77-98.
4. Ransohoff, R. M.; Perry, V. H. Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol., 2009, 27(119- 145).
5. Block, M. L.; Zecca, L.; Hong, J. S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci., 2007, 8(1), 57-69.
6. Hanisch, U. Microglia as a source and target of cytokines. Glia, 2002, 40(2), 140-155.
7. McGeer, P. L.; Kawamata, T.; Walker, D. G.; Akiyama, H.; Tooyama, I.; McGeer, E. G. Microglia in degenerative neurological disease. Glia, 1993, 7(1), 84-92.
8. Hanisch, U. K.; Kettenmann, H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci., 2007, 10(11), 1387-1394.
9. Inoue, K.; Tsuda, M. Microglia and neuropathic pain. Glia, 2009, 57(14), 1469-1479.
10. Shenton, M. E.; Dickey, C. C.; Frumin, M.; McCarley, R. W. A review of MRI findings in schizophrenia. Schizophr. Res., 2001, 49(1-2), 1-52.
11. Salisbury, D. F.; Kuroki, N.; Kasai, K.; Shenton, M. E.; McCarley, R. W. Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch. Gen. Psychiatry, 2007, 64(5), 521-529.
12. Lieberman, J. A.; Tollefson, G. D.; Charles, C.; Zipursky, R.; Sharma, T.; Kahn, R. S.; Keefe, R. S.; Green, A. I.; Gur, R. E.; McEvoy, J.; Perkins, D.; Hamer, R. M.; Gu, H.; Tohen, M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry, 2005, 62(4), 361-370.
13. Steiner, J.; Bielau, H.; Brisch, R.; Danos, P.; Ullrich, O.; Mawrin, C.; Bernstein, H. G.; Bogerts, B. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res, 2008, 42(2), 151-157.
14. Radewicz, K.; Garey, L. J.; Gentleman, S. M.; Reynolds, R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J. Neuropathol. Exp. Neurol., 2000, 59(137-150).
15. van Berckel, B. N.; Bossong, M. G.; Boellaard, R.; Kloet, R.; Schuitemaker, A.; Caspers, E.; Luurtsema, G.; Windhorst, A. D.; Cahn, W.; Lammertsma, A. A.; Kahn, R. S. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry, 2008, 64(9), 820-822.
16. Doorduin, J.; de Vries, E.; Willemsen, A.; de Groot, J.; Dierckx, R.; Klein, H. Neuroinflammation in schizophrenia-related psychosis: a PET study. J. Nucl. Med., 2009, 50, 1801-1807.
17. Takano, A.; Arakawa, R.; Ito, H.; Tateno, A.; Takahashi, H.; Matsumoto, R.; Okubo, Y.; Suhara, T. Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int. J. Neuropsychopharmacol, 2010, 13(7), 943-950.
18. Muller, N.; Krause, D.; Dehning, S.; Musil, R.; Schennach-Wolff, R.; Obermeier, M.; Moller, H. J.; Klauss, V.; Schwarz, M. J.; Riedel, M. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr. Res., 2010, 121(1-3), 118-124.
19. Miyaoka, T.; Yasukawa, R.; Yasuda, H.; Hayashida, M.; Inagaki, T.; Horiguchi, J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin. Neuropharmacol., 2008, 31(5), 287-292.
20. Akhondzadeh, S.; Tabatabaee, M.; Amini, H.; Ahmadi Abhari, S. A.; Abbasi, S. H.; Behnam, B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr. Res., 2007, 90(1-3), 179-185.
21. Kato, T.; Monji, A.; Hashioka, S.; Kanba, S. Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophr. Res., 2007, 92(1-3), 108-115.
22. Bian, Q.; Kato, T.; Monji, A.; Hashioka, S.; Mizoguchi, Y.; Horikawa, H.; Kanba, S. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32(1), 42-48.
23. 2+ regulation in vitro. J. Neurochem., 2008, 106(2), 815-825.
24. Kato, T. A.; Monji, A.; Yasukawa, K.; Mizoguchi, Y.; Horikawa, H.; Seki, Y.; Hashioka, S.; Han, Y. H.; Kasai, M.; Sonoda, N.; Hirata, E.; Maeda, Y.; Inoguchi, T.; Utsumi, H.; Kanba, S. Aripiprazole inhibits superoxide generation from phorbolmyristate- acetate (PMA)- stimulated microglia in vitro: implication for antioxidative psychotropic actions via microglia. Schizophr. Res., In press.
25. Alzheimer, A. Beitrage zur pathologischen anatomie der hirnrinde und zur anatomischen grundlage einiger psychosen. Monatsschrift fur Psychiarie und Neurologie, 1897, 2, 82-120.
26. Iritani, S. Neuropathology of schizophrenia: a mini review. Neuropathology, 2007, 27(6), 604-608.
27. Miyamoto, S.; Duncan, G. E.; Marx, C. E.; Lieberman, J. A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry., 2005, 10(1), 79-104.
28. Kapur, S.; Mamo, D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol. Psychiatry, 2003, 27(7), 1081-1090.
29. Kim, J. S.; Kornhuber, H. H.; Schmid-Burgk, W.; Holzmuller, B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett., 1980, 20(3), 379-382.
30. Goff, D. C.; Coyle, J. T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry, 2001, 158(9), 1367-1377.
31. Lieberman, J. A. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol. psychiatry, 1999, 46(6), 729-739.
32. Lieberman, J. A.; Stroup, T. S.; McEvoy, J. P.; Swartz, M. S.; Rosenheck, R. A.; Perkins, D. O.; Keefe, R. S.; Davis, S. M.; Davis, C. E.; Lebowitz, B. D.; Severe, J.; Hsiao, J. K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med., 2005, 353(12), 1209-1223.
33. Leucht, S.; Corves, C.; Arbter, D.; Engel, R. R.; Li, C.; Davis, J. M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 2009, 373(9657), 31-41.
34. Kowalski, J.; Labuzek, K.; Herman, Z. S. Flupentixol and trifluperidol reduce secretion of tumor necrosis factor-alpha and nitric oxide by rat microglial cells. Neurochem. Int., 2003, 43, 173-178.
35. Kowalski, J.; Labuzek, K.; Herman, Z. S. Flupentixol and trifluperidol reduce interleukin-1 beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Pol. J. Pharmacol., 2004, 56, 563-570.
36. Labuzek, K.; Kowalski, J.; Gabryel, B.; Herman, Z. S. Chlorpromazine and loxapine reduce interleukin-1beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Eur. Neuropsychopharmacol., 2005, 15, 23-30.
37. Hou, Y.; Wu, C. F.; Yang, J. Y.; He, X.; Bi, X. L.; Yu, L.; Guo, T. Effects of clozapine, olanzapine and haloperidol on nitric oxide production by lipopolysaccharide-activated N9 cells. Prog Neuropsychopharmacol Biol. Psychiatry, 2006, 30(8), 1523-1528.
38. Zheng, L. T.; Hwang, J.; Ock, J.; Lee, M. G.; Lee, W. H.; Suk, K. The antipsychotic spiperone attenuates inflammatory response in cultured microglia via the reduction of proinflammatory cytokine expression and nitric oxide production. J. Neurochem., 2008, 107(5), 1225-1235.
39. Shapiro, D. A.; Renock, S.; Arrington, E.; Chiodo, L. A.; Liu, L. X.; Sibley, D. R.; Roth, B. L.; Mailman, R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 2003, 28(8), 1400-1411.
40. Burris, K. D.; Molski, T. F.; Xu, C.; Ryan, E.; Tottori, K.; Kikuchi, T.; Yocca, F. D.; Molinoff, P. B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther., 2002, 302(1), 381-389.
41. Potkin, S. G.; Saha, A. R.; Kujawa, M. J.; Carson, W. H.; Ali, M.; Stock, E.; Stringfellow, J.; Ingenito, G.; Marder, S. R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry, 2003, 60(7), 681-690.
42. Pocock, J. M.; Kettenmann, H. Neurotransmitter receptors on microglia. Trends. Neurosci., 2007, 30(10), 527-535.
43. Lu, X. H.; Dwyer, D. S. Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways. J. Mol. Neurosci., 2005, 27(1), 43-64.
44. Nikodemova, M.; Duncan, I.D.; Watters, J.J. Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and IkappaBalpha degradation in a stimulus-specific manner in microglia. J. Neurochem., 2006, 96(2), 314-323.
45. Schonwasser, D.C.; Marais, R.M.; Marshall, C. J.; Parker, P.J. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol. Cell Biol., 1998, 18(2), 790-798.
46. Kim, H.S.; Whang, S.Y.; Woo, M. S.; Park, J. S.; Kim, W. K.; Han, I.O. Sodium butyrate suppresses interferon-gamma-, but not lipopolysaccharide-mediated induction of nitric oxide and tumor necrosis factor-alpha in microglia. J. Neuroimmunol., 2004, 151(1- 2), 85-93.
47. Park, J. S.; Woo, M. S.; Kim, S. Y.; Kim, W. K.; Kim, H. S. Repression of interferon-gamma-induced inducible nitric oxide synthase (iNOS) gene expression in microglia by sodium butyrate is mediated through specific inhibition of ERK signaling pathways. J. Neuroimmunol., 2005, 168(1-2), 56-64.
48. Lidow, M. S. Calcium signaling dysfunction in schizophrenia: a unifying approach. Brain. Res. Brain Res. Rev., 2003, 43(1), 70-84.
49. Ng, F.; Berk, M.; Dean, O.; Bush, A. I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol., 2008, 11(6), 851-876.
50. Yao, J. K.; Reddy, R. D.; van Kammen, D. P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs, 2001, 15(4), 287-310.
51. Zhang, X. Y.; Chen da, C.; Xiu, M. H.; Wang, F.; Qi, L. Y.; Sun, H. Q.; Chen, S.; He, S. C.; Wu, G. Y.; Haile, C. N.; Kosten, T. A.; Lu, L.; Kosten, T. R. The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients. Schizophr. Res., 2009, 113(2-3), 151-157.
52. Lavoie, S.; Murray, M. M.; Deppen, P.; Knyazeva, M. G.; Berk, M.; Boulat, O.; Bovet, P.; Bush, A. I.; Conus, P.; Copolov, D.; Fornari, E.; Meuli, R.; Solida, A.; Vianin, P.; Cuenod, M.; Buclin, T.; Do, K. Q. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology, 2008, 33(9), 2187-2199.
53. Berk, M.; Copolov, D.; Dean, O.; Lu, K.; Jeavons, S.; Schapkaitz, I.; Anderson-Hunt, M.; Judd, F.; Katz, F.; Katz, P.; Ording- Jespersen, S.; Little, J.; Conus, P.; Cuenod, M.; Do, K. Q.; Bush, A. I. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol. Psychiatry, 2008, 64(5), 361-368.
54. Zhang, X. Y.; Zhou, D. F.; Qi, L. Y.; Chen, S.; Cao, L. Y.; Chen da, C.; Xiu, M. H.; Wang, F.; Wu, G. Y.; Lu, L.; Kosten, T. A.; Kosten, T. R. Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. Psychopharmacology (Berl), 2009, 204(1), 177-184.
55. Wang, J. Y.; Wen, L.L.; Huang, Y.N.; Chen, Y.T.; Ku, M.C. Dual effects of antioxidants in neurodegeneration: direct neuroprotection against oxidative stress and indirect protection via suppression of glia-mediated inflammation. Curr. Pharm. Des., 2006, 12(27), 3521-3533.
56. Zhang, Y.; Xu, H.; Jiang, W.; Xiao, L.; Yan, B.; He, J.; Wang, Y.; Bi, X.; Li, X.; Kong, J.; Li, X. M. Quetiapine alleviates the cuprizone-induced white matter pathology in the brain of C57BL/6 mouse. Schizophr. Res., 2008, 106(2-3), 182-191.
57. Arif, M.; Chikuma, T.; Ahmed, M. M.; Yoshida, S.; Kato, T. Suppressive effect of clozapine but not haloperidol on the increases of neuropeptide-degrading enzymes and glial cells in MK-801- treated rat brain regions. Neurosci. Res., 2007, 57(2), 248-258.
58. Nakki, R.; Nickolenko, J.; Chang, J.; Sagar, S. M.; Sharp, F. R. Haloperidol prevents ketamine- and phencyclidine-induced HSP70 protein expression but not microglial activation. Exp. Neurol., 1996, 137(2), 234-241.
59. Quincozes-Santos, A.; Bobermin, L. D.; Tonial, R. P.; Bambini- Junior, V.; Riesgo, R.; Gottfried, C. Effects of atypical(risperidone) and typical (haloperidol) antipsychotic agents on astroglial functions. Eur. Arch. Psychiatry Clin. Neurosci., 260(6), 475-481.
60. Quincozes-Santos, A.; Bobermin, L. D.; Kleinkauf-Rocha, J.; Souza, D. O.; Riesgo, R.; Goncalves, C. A.; Gottfried, C. Atypical neuroleptic risperidone modulates glial functions in C6 astroglial cells. Prog Neuropsychopharmacol Biol. Psychiatry, 2009, 33(1), 11-15.
61. Vallejo-Illarramendi, A.; Torres-Ramos, M.; Melone, M.; Conti, F.; Matute, C. Clozapine reduces GLT-1 expression and glutamate uptake in astrocyte cultures. Glia, 2005, 50(3), 276-279.
62. Steiner, J.; Schroeter, M. L.; Schiltz, K.; Bernstein, H. G.; Muller, U. J.; Richter-Landsberg, C.; Muller, W. E.; Walter, M.; Gos, T.; Bogerts, B.; Keilhoff, G. Haloperidol and clozapine decrease S100B release from glial cells. Neuroscience, 167(4), 1025-1031.
63. Quincozes-Santos, A.; Abib, R. T.; Leite, M. C.; Bobermin, D.; Bambini-Junior, V.; Goncalves, C. A.; Riesgo, R.; Gottfried, C. Effect of the atypical neuroleptic risperidone on morphology and S100B secretion in C6 astroglial lineage cells. Mol. Cell Biochem., 2008, 314(1-2), 59-63.
64. Wake, H.; Moorhouse, A. J.; Jinno, S.; Kohsaka, S.; Nabekura, J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J. Neurosci., 2009, 29(13), 3974-3980.
65. Graeber, M. B. Changing face of microglia. Science, 2010, 330(6005), 783-788.
66. Sugama, S.; Takenouchi, T.; Fujita, M.; Conti, B.; Hashimoto, M. Differential microglial activation between acute stress and lipopolysaccharide treatment. J. Neuroimmunol., 2009, 207(1-2), 24-31.
67. Frank, M. G.; Baratta, M. V.; Sprunger, D. B.; Watkins, L. R.; Maier, S. F. Microglia serve as a neuroimmune substrate for stressinduced potentiation of CNS pro-inflammatory cytokine responses. Brain Behav. Immun., 2007, 21(1), 47-59.
68. Schiavone, S.; Sorce, S.; Dubois-Dauphin, M.; Jaquet, V.; Colaianna, M.; Zotti, M.; Cuomo, V.; Trabace, L.; Krause, K. H. Involvement of NOX2 in the development of behavioral and pathologic alterations in isolated rats. Biol. Psychiatry, 2009, 66(4), 384-392.
69. Neigh, G. N.; Karelina, K.; Glasper, E. R.; Bowers, S. L.; Zhang, N.; Popovich, P. G.; DeVries, A. C. Anxiety after cardiac arrest/cardiopulmonary resuscitation: exacerbated by stress and prevented by minocycline. Stroke, 2009, 40(11), 3601-3607.
70. Jones, P.; Rodgers, B.; Murray, R.; Marmot, M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet, 1994, 344(8934), 1398-1402.
71. Jaaro-Peled, H.; Hayashi-Takagi, A.; Seshadri, S.; Kamiya, A.; Brandon, N. J.; Sawa, A. Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. Trends Neurosci., 2009, 32(9), 485-495.
72. Gogtay, N.; Giedd, J. N.; Lusk, L.; Hayashi, K. M.; Greenstein, D.; Vaituzis, A. C.; Nugent, T. F., 3rd; Herman, D. H.; Clasen, L. S.; Toga, A. W.; Rapoport, J. L.; Thompson, P. M. Dynamic mapping of human cortical development during childhood through early adulthood. Proc. Natl. Acad. Sci. U. S. A., 2004, 101(21), 8174- 8179.
73. van Winkel, R.; Stefanis, N. C.; Myin-Germeys, I. Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. Schizophr. Bull., 2008, 34(6), 1095-1105.
74. Dalman, C.; Allebeck, P.; Gunnell, D.; Harrison, G.; Kristensson, K.; Lewis, G.; Lofving, S.; Rasmussen, F.; Wicks, S.; Karlsson, H. Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects. Am. J. Psychiatry, 2008, 165(1), 59-65.
75. Mortensen, P. B.; Pedersen, C. B.; Hougaard, D. M.; Norgaard- Petersen, B.; Mors, O.; Borglum, A. D.; Yolken, R. H. A Danish National Birth Cohort study of maternal HSV-2 antibodies as a risk factor for schizophrenia in their offspring. Schizophr. Res., 2010, 122(1-3), 257-263.
76. Jia, P.; Wang, L.; Meltzer, H. Y.; Zhao, Z. Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophr. Res., 2010, 122(1-3), 38-42.
77. Kawanokuchi, J.; Mizuno, T.; Takeuchi, H.; Kato, H.; Wang, J.; Mitsuma, N.; Suzumura, A. Production of interferon-gamma by microglia. Mult. Scler., 2006, 12(5), 558-564.
78. Cazzullo, C. L.; Sacchetti, E.; Galluzzo, A.; Panariello, A.; Adorni, A.; Pegoraro, M.; Bosis, S.; Colombo, F.; Trabattoni, D.; Zagliani, A.; Clerici, M. Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2002, 26(1), 33-39.
79. Cazzullo, C. L.; Sacchetti, E.; Galluzzo, A.; Panariello, A.; Colombo, F.; Zagliani, A.; Clerici, M. Cytokine profiles in drugnaive schizophrenic patients. Schizophr. Res., 2001, 47(293-298).
80. Glantz, L. A.; Gilmore, J. H.; Lieberman, J. A.; Jarskog, L. F. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr. Res., 2006, 81(1), 47-63.
81. Reif, A.; Fritzen, S.; Finger, M.; Strobel, A.; Lauer, M.; Schmitt, A.; Lesch, K. P. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol. Psychiatry, 2006, 11(5), 514-522.
82. Schlosser, R. G.; Nenadic, I.; Wagner, G.; Gullmar, D.; von Consbruch, K.; Kohler, S.; Schultz, C. C.; Koch, K.; Fitzek, C.; Matthews, P. M.; Reichenbach, J. R.; Sauer, H. White matter abnormalities and brain activation in schizophrenia: a combined DTI and fMRI study. Schizophr. Res, 2007, 89(1-3), 1-11.
83. Davis, K. L.; Stewart, D. G.; Friedman, J. I.; Buchsbaum, M.; Harvey, P. D.; Hof, P. R.; Buxbaum, J.; Haroutunian, V. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch. Gen. Psychiatry, 2003, 60(5), 443-456.
84. Uranova, N. A.; Vostrikov, V. M.; Vikhreva, O. V.; Zimina, I. S.; Kolomeets, N. S.; Orlovskaya, D. D. The role of oligodendrocyte pathology in schizophrenia. Int. J. Neuropsychopharmacol., 2007, 10(4), 537-545.
85. Qin, B.; Cartier, L.; Dubois-Dauphin, M.; Li, B.; Serrander, L.; Krause, K. H. A key role for the microglial NADPH oxidase in APP-dependent killing of neurons. Neurobiol. Aging, 2006, 27(11), 1577-1587.
86. Iosif, R. E.; Ekdahl, C. T.; Ahlenius, H.; Pronk, C. J.; Bonde, S.; Kokaia, Z.; Jacobsen, S. E.; Lindvall, O. Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J. Neurosci., 2006, 26(38), 9703-9712.
87. Kaneko, N.; Kudo, K.; Mabuchi, T.; Takemoto, K.; Fujimaki, K.; Wati, H.; Iguchi, H.; Tezuka, H.; Kanba, S. Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology, 2006, 31(12), 2619-2626.
88. Monje, M. L.; Toda, H.; Palmer, T. D. Inflammatory blockade restores adult hippocampal neurogenesis. Science, 2003, 302(5651), 1760-1765.
89. Cardenas, A.; Moro, M. A.; Hurtado, O.; Leza, J. C.; Lizasoain, I. Dual role of nitric oxide in adult neurogenesis. Brain Res. Brain Res. Rev., 2005, 50(1), 1-6.
90. Merrill, J. E.; Ignarro, L. J.; Sherman, M. P.; Melinek, J.; Lane, T. E. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol., 1993, 151(4), 2132-2141.
91. Li, J.; Baud, O.; Vartanian, T.; Volpe, J. J.; Rosenberg, P. A. Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc. Natl. Acad. Sci. U. S. A., 2005, 102(28), 9936-9941.
92. Buntinx, M.; Moreels, M.; Vandenabeele, F.; Lambrichts, I.; Raus, J.; Steels, P.; Stinissen, P.; Ameloot, M. Cytokine-induced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFN-gamma and TNF-alpha on apoptosis. J. Neurosci. Res., 2004, 76(6), 834-845.
93. Abekawa, T.; Ito, K.; Nakagawa, S.; Nakato, Y.; Koyama, T. Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents. Schizophr. Res., 2011, 125(1), 77-87.
94. Wang, H. D.; Dunnavant, F. D.; Jarman, T.; Deutch, A. Y. Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology, 2004, 29(7), 1230-1238.
95. Wakade, C. G.; Mahadik, S. P.; Waller, J. L.; Chiu, F. C., Atypical neuroleptics stimulate neurogenesis in adult rat brain. J. Neurosci. Res., 2002, 69(1), 72-79.
96. Halim, N. D.; Weickert, C. S.; McClintock, B. W.; Weinberger, D. R.; Lipska, B. K. Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology, 2004, 29(6), 1063-1069.
97. Bartzokis, G.; Lu, P. H.; Stewart, S. B.; Oluwadara, B.; Lucas, A. J.; Pantages, J.; Pratt, E.; Sherin, J. E.; Altshuler, L. L.; Mintz, J.; Gitlin, M. J.; Subotnik, K. L.; Nuechterlein, K. H. In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia. Schizophr. Res., 2009, 113(2-3), 322-331.
98. Raison, C. L.; Capuron, L.; Miller, A. H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends. Immunol., 2006, 27(1), 24-31.
99. Dantzer, R.; O'Connor, J. C.; Freund, G. G.; Johnson, R. W.; Kelley, K. W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci., 2008, 9(1), 46-56.
100. Weber, J.; Lyseng-Williamson, K. A.; Scott, L. J. Aripiprazole: in major depressive disorder. CNS Drugs, 2008, 22(10), 807-813.
101. Mohamed, S.; Leslie, D. L.; Rosenheck, R. A. Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of veterans affairs. J Clin. Psychiatry, 2009, 70(6), 906-912.
102. Eren, I.; Naziroglu, M.; Demirdas, A. Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain. Neurochem. Res., 2007, 32(7), 1188-1195.